Citations

Clear

9383 citation(s) found for "Thomas, PS".

Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer
Khan, Fahad, Polydorides, Alexandros D., Paulsen, John D., Chen, W, Vazzano, Jennifer , Huber, Aaron , Papke, David, Sharifai, Nima , Allende, Daniela, McHugh, Kelsey, Longacre, Teri A. , Dhall, Deepti, Makhoul, Elias, Lee, Michael J., Collins, Katrina, Ulbright, Thomas M. , Zhang, M. Lisa, Westerhoff, Maria , Gao, Zu‐Hua , Choi, Won‐Tak , Kakar, Sanjay, Chetty, Runjan, Nowak, Klaudia, Zhang, Xuchen, Chen, Wei , McHugh, Kelsey , Khan, Fahad , Gonzalez, Raul S , Chen, Wei , McHugh, Kelsey E , Polydorides, Alexandros D. , Paulsen, John David , Papke, David , Stashek, Kristen , Ruz‐Caracuel, Ignacio , Shia, Jinru , Dhall, Deepti , Collins, Katrina , Zhang, Mingjuan Lisa , Matsukuma, Karen , Kakar, Sanjay , Chetty, Runjan , Nowak, Klaudia M. , Serra, Stefano , González, Raul S.

Mayo Clinic

American Journal of Surgical Pathology | April 21, 2026 | Volume: 50 | Issue: 8 | Pages: 883-893

10.1097/pas.0000000000002555 | PMID 42012857 Get It

Enteroblastic, hepatoid, and clear cell carcinomas are rare subtypes of colorectal carcinoma (CRC) with histologic and immunohistochemical (IHC) overlap. We assessed 37 CRCs that possibly represent these subtypes. Provisional criteria for each subtype, along with case photomicrographs and IHC data, were circulated among the authors to provide diagnostic interpretations. Based on plurality consensus, the carcinomas were classified as enteroblastic (n=13), hepatoid (n=6), and clear cell (n=18). Unanimous agreement was reached in 18% (3 clear cell, 3 hepatoid). Interobserver analysis revealed a mean pairwise Cohen κ of 0.63 (range: 0.32 to 0.91), with the hepatoid subtype eliciting the greatest consensus. Clear cell areas were the most likely to intermix with areas of conventional CRC ( P <0.001). Seven patients (20%) had inflammatory bowel disease (mostly linked to enteroblastic CRC). Twenty-three of 34 patients (68%) had nodal metastasis, and 12 (32%) had distant metastasis (mostly to the liver) at presentation. Median recurrence-free survival was 17 months, with enteroblastic cases the most likely to recur (54%, P =0.015). Median follow-up length was 27 months, with 14 patients (40%) dying of disease (representing 7 enteroblastic, 4 hepatoid, and 3 clear cell CRC). Mutations were identified in TP53 (n=8) , APC (n=3) , FBXW7 (n=2), and KRAS (n=1). Inflammatory bowel disease significantly worsened recurrence-free survival on multivariate analysis, while distant metastasis significantly worsened both recurrence-free and overall survival on multivariate analysis. Enteroblastic, hepatoid, and clear cell CRC demonstrate morphologic and IHC overlap, leading to interobserver variability in diagnosis. Given potential differences in clinical correlations and outcomes, more refined criteria are likely necessary.
Standardized Perioperative Protocols Are Associated With Reduced Length of Stay and Readmission in Cushing Disease: Results From the Multicenter RAPID Study
Suryadevara, Carter M. , Salcedo-Sifuentes, Jorge E., Little, Andrew S., Yuen, Kevin C. J., Mendoza, Michelle Magana, Gardner, Paul, Zenonos, Georgios, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Couldwell, William T., Rennert, Robert C., Kim, Won, Kshettry, Varun R., Wu, Kyle, BENJAMIN, CAROLINA, Zada, Gabriel, Gompel, Jamie Van, Catalino, Michael P., Karsy, Michael, Rosenberg, Yaakov, Mamelak, Adam N, Agrawal, Nidhi , Pacione, Donato , Karsy, Michael , Van Gompel, Jamie, Karsy, Michael , Salcedo-Sifuentes, Jorge E. , Little, Andrew S. , Yuen, Kevin C.J. , Zenonos, Georgios A, Silverstein, Julie , Kim, Albert H , Evans, James J., Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Couldwell, William T. , Rennert, Robert C , Kshettry, Varun R. , Zada, Gabriel , Chicoine, Michael , Gompel, Jamie J. Van , Catalino, Michael Paul, Agrawal, Nidhi

Mayo Clinic

Neurosurgery | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000003992 | PMID 42012163 Get It

BACKGROUND AND OBJECTIVES: Perioperative protocols facilitate earlier discharge without compromising safety in nonfunctioning pituitary adenomas, but no large multicenter studies in the United States have investigated protocols regarding Cushing disease (CD). We sought to characterize perioperative protocols and how their implementation influences clinical outcomes in patients with CD. METHODS: A retrospective analysis was conducted using data from the Registry of Adenomas of the Pituitary and Related Disorders consortium comprising 13 US academic pituitary centers. Institutions were surveyed regarding perioperative procedures for patients undergoing transsphenoidal tumor resection for CD. The impacts of institutional procedures and approaches to implementation on length of stay (LOS) and unplanned 90-day readmission were evaluated. RESULTS: Thirteen institutions contributed survey responses and clinical data for a total of 832 patients meeting inclusion criteria. Ten (76.9%) institutions reported having a postoperative protocol, 9 (69.2%) used a formal document to outline their protocol, and 3 (23.1%) had protocols implemented into hospital policy. Mean LOS was significantly reduced in centers with an established protocol (3.14 vs 3.42 days, P = .032), and more so with a formal document (3.10 vs 3.48 days, P = .001) or hospital policy (2.72 vs 3.36 days, P < .001). Patients treated after protocol implementation experienced shorter LOS ( P < .001). Other factors associated with reduced LOS were presence of a separate CD pathway, intraoperative checklist specific to pituitary surgery, non-narcotic pain regimen, Foley removal order, dedicated outpatient advanced practice provider follow-up, and target discharge date ≤2 days. Intraoperative checklist ( P = .045), non-narcotic pain regimen ( P = .048), nasal packing ( P = .005), and 1-day target discharge date ( P = .032) were important factors against readmission. Compared with microscopic surgery, endoscopic surgery was associated with shorter LOS but increased readmission odds. CONCLUSION: This is the first multicenter study to illustrate that implementation of perioperative protocols is associated with a reduction in LOS and readmission risk in patients with CD.
Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays
Janarthanam, Chelva, Hughson, Andrew G, Holzinger, David, Taylor, Keenan, Caughey, Byron, Adler, Charles H, Shill, Holly A, Mehta, SH, Driver-Dunckley, Erika, Ho, Andrew H, Shprecher, David R, Belden, Christine M. , Atri, Alireza, Zhang, Nan, Chen, Kewei, Serrano, Geidy E, Beach, T, Beach, Thomas G , Orru, Christina Doriana , Hughson, Andrew G. , Kanthasamy, Anumantha G. , Caughey, Byron W. , Heym, Roland G. , Adler, Charles H. , Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika , Choudhury, Parichita , Shprecher, David , Atri, A., Serrano, Geidy E. , Beach, Thomas G.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnen/nlag048 | PMID 42223057 Get It

Abstract Skin biopsies analyzed with α-synuclein seed amplification assays (SAAs) are a simple way to clinically interrogate the presence of α-synuclein aggregates. We determined the accuracy of skin biopsy SAA in predicting the clinical diagnoses of Parkinson disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB). Blinded SAAs were performed in 3 independent laboratories. Subjects diagnosed with PD, PDD and DLB were analyzed together as group 1, clinically unaffected subjects as group 2 and those with risk factors for LBD as group 3. Punch biopsies were taken from the posterior neck and analyzed by the 3 labs in 6 separate SAAs. Pairwise agreement between labs and assays ranged from excellent (kappa 0.82) to moderate (kappa 0.40-0.68). Sensitivity across assays ranged between 50.0% and 61.3%; specificity ranged between 68.6% and 100%. Comparisons of group 1 vs group 2 produced the greatest specificities, between 77.3% and 100%. In 17 cases that subsequently came to autopsy, 93% of SAAs were positive in those at the neocortical LBD stage but in only &lt;10% of those at lower stages. Skin biopsy α-synuclein SAA may be useful as a diagnostic and progression biomarker in Lewy body dementia clinical trials.
World Health Organization classification of tumours of the breast 6th edition 2026
Quinn, Cecily , Tan, Puay Hoon , Allison, Kimberly H. , Brogi, Edi , Lakhani, Sunil R. , Schnitt, Stuart J. , Fox, Stephen B. , Jaffer, Shabnam , Şahin, Ayşegül A. , Salgado, Roberto , Adjei, E, Helbich, Thomas H. , Sotiriou, C, Hodge, Jennelle C. , Khoury, Joseph D. , Puspanathan, Pavitratha, Giesen, Christine, Ruiz, Blanca Iciar Indave , Ellis, Ian, Lokuhetty, Dilani , Board, WCT Standing Editorial, Netto, George J. , Sahin, Aysegul , Sapino, Anna , Adjei, Ernest Kwasi , Geiersbach, Katherine , Helbich, Thomas H , Lambertini, Matteo , Sotiriou, Christos P. , Hodge, Jennelle C , Khoury, Joseph , Rekhi, Bharat , Ryska, Ales , Tse, Gary , Field, Andrew , Wijesinghe, Harshima , Puspanathan, Pavitratha , Giesen, Christine , Ruiz, Blanca Iciar Indave , Ellis, Ian , Lokuhetty, Dilani , Geiersbach, Katherine B. , Lambertini, Matteo , Field, Andrew , Ellis, Ian O. , board, WCT standing editorial

Mayo Clinic

Histopathology | April 21, 2026 | Volume: 89 | Issue: 2 | Pages: 199-218

10.1111/his.70149 | PMID 42011085 Get It

The 6th edition of the WHO Classification of Breast Tumours introduces both major and minor changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimens necessitating modifications to pathology reporting and tumour biomarker categorisation. This review summarises the main changes that strive towards a classification of global relevance. In invasive carcinoma, predictive factors increasingly inform modern breast cancer treatment. The 6th edition provides an update on HER2 reporting categories following the DESTINY‐Breast 04 and 06 trials. Terminologies used to classify invasive tumours are clarified, with the term ‘variant’ now reserved for molecular/genetic alterations. Invasive lobular carcinoma (ILC) with extracellular mucin is recognised as a new diagnostic entity with prognostic implications. The diagnosis of mucinous carcinoma (MC) is reserved for mucin secreting carcinomas with grade 1 or 2 morphology and a favourable biomarker profile. The diagnosis of malignant phyllodes tumours requires only four of the original five adverse histological criteria. Classification of neuroendocrine tumours (NETs) is revised, recognising that the unified model, promoted in the 5th edition, is difficult to apply to the breast. New approaches to the classification of adenomyoepithelioma are discussed but the 5th edition system is broadly retained. A new section on ‘Small Diagnostic Samples’ outlines the merits of non‐operative biopsy diagnosis, the B coding system and the importance of multidisciplinary review. Changes to diagnostic practice and the emerging role of artificial intelligence, with advantages and challenges, are discussed in a new section on ‘Digital Pathology’.
Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia
Banerjee, Ritu, Komarow, Lauren , Li, Yixuan, Mau, Donald, Geres, Holly, Greenwood-Quaintance, Kerryl, Adler, Amos , Baliga, S, Chrysos, George , Zarkotou, Olympia , Paul, Mical, Regueiro, Dolores Sousa, Chambers, Henry, Fowler, Vance G., Patel, Robin, Group, Antibacterial Resistance Leadership, Chambers, Henry F. , Cross, Heather, Harris, Anthony D. , Duin, David van, Boucher, Helen W., Huntley, Clayton C., Raterman, Erica L., Samuel, Tamika, Moon, Kyung, Holland, Thomas L., Lodise, Thomas, Shelburne, Samuel A. , Cosgrove, Sara E., Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah B. , Perdue, Sam, Singh, Tara A. , Wickward, Cathy, Souto, David A., Waller, Jason, Evans, Scott R , Banerjee, Ritu , Dodd, Andrew, Geres, Holly, Greenwood‐Quaintance, Kerryl E. , Baliga, Shrikala , Chowers, Michal , Paul, Mical, Pournaras, Spyros , Fowler, Vance G. , Patel, Robin , Evans, Scott , Hamasaki, Toshimitsu , Pettigrew, Melinda M. , Hanson, Kimberly E. , Doi, Yohei , Holland, Thomas L. , Cosgrove, Sara E. , Paterson, David L.

Mayo Clinic

JAMA | April 18, 2026 | Volume: 335 | Issue: 20 | Pages: 1762

10.1001/jama.2026.5487 | PMID 41999287 Get It

Importance Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact. Objective To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance. Design, Setting, and Participants Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026. Intervention Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations. Main Outcomes and Measures The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days. Results Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, −18 hours [95% CI, −42 to 6]). Conclusions and Relevance Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT06174649
ADLM Guidance Document on Incorporating Gender Diversity in Pathology and Laboratory Medicine
Thomas, Tiffany, Winston‐McPherson, Gabrielle , Amarillo, Pérez, Berry, Alisha D. , Davidge‐Pitts, Caroline , Devaraj, Sridevi, Goldstein, Zil, Karon, Brad S. , Katzman, Brooke M. , Khalifa, Mahmoud A. , Stockley, Tracy L, Stoffel, Michelle , Davidge-Pitts, Caroline , Luu, Hung S , Nichols, James H , Stoffel, Michelle R , Greene, Dina , Krasowski, Matthew D , Amarillo, Ina, Devaraj, Sridevi , Goldstein, Zil , Luu, Hung S. , Nichols, James H. , Stockley, Tracy , Greene, Dina N. , Krasowski, Matthew D.

Mayo Clinic

The Journal of Applied Laboratory Medicine | April 18, 2026 | Volume: 11 | Issue: 4 | Pages: 887-926

10.1093/jalm/jfag071 | PMID 42383916 Get It

Abstract Background The first international clinical standards of care for the gender-diverse population were formulated in the late 1970s. In the last 15 years, multiple subspecialty societies within the United States have developed clinical care guidelines for those with gender dysphoria, including gender-affirming hormone therapy (GAHT) and surgical treatments. To date, there are no pathology- and laboratory medicine–specific recommendations in the United States for the gender-diverse population. Content This document outlines pathology- and laboratory medicine–specific recommendations for providing optimal care to the gender-diverse population, with a predominant focus on the adult population. The scope of this document focuses on the following 5 topics: (a) reference intervals and interpretation of laboratory tests impacted by use of GAHT (testosterone for transgender men; estradiol with or without antiandrogens for transgender women), focusing on those stably on GAHT for 6 months or longer; (b) transfusion medicine considerations for the gender-diverse patient population, (c) consideration of gender diversity in autopsy and death investigation, (d) interpretation of histology from tissues that are impacted by GAHT and surgical procedures; and (e) pathology and laboratory medicine informatics challenges and opportunities. Summary A relatively small group of laboratory tests is significantly impacted by GAHT. The histology of some tissues shows changes attributable to GAHT or to nonhormonal medical procedures. Autopsy and transfusion medicine practices for the gender-diverse population currently lack standardization, although this is evolving. The landscape of pathology informatics related to gender diversity is complicated by varying electronic health record and laboratory informatics systems functionality.
Patient's Age Impact on Stroke Risk and Intracranial Aneurysm Occlusion: SCENT Flow Diverter Study—A Nonrandomized Clinical Trial on Large and Giant Aneurysms
Wakhloo, Ajay K. , Jenkins, Paul, Meyers, Philip M. , Coon, A , Kan, Peter T., Puri, Ajit S., Vries, Joost de, Lanzino, Giuseppe, Bain, Mark D., Ebersole, Koji , Welch, B, Dog⫧an, Aclan , Jabbour, Pascal M., Mocco, J., Siddiqui, Adnan H., Turk, Aquilla S., Taussky, Philipp, Hanel, Ricardo A., Investigators, for the SHaRe and IPHCC, Siddiqui, Adnan H. , Siddiqui, Adnan H , Coon, Alexander Lewis , Kan, Peter , Puri, Ajit S., Vries, Joost de , Lanzino, Giuseppe , Welch, Babu G. , Jabbour, Pascal , Turk, Aquilla S , Taussky, Philipp , Hanel, Ricardo A.

Mayo Clinic

Neurosurgery Practice | April 17, 2026 | Volume: 7 | Issue: 2 | Pages: No page available

10.1227/neuprac.0000000000000222 | PMID 42007246 Get It

BACKGROUND AND OBJECTIVES: The prospective single-arm nonrandomized SCENT (Surpass Intracranial Aneurysm Embolization System Pivotal) trial on flow diverter treatment of large and giant intracranial aneurysms (IA) was analyzed for patients' age and IA characteristics affecting stroke and occlusion rates over 5 years (Trial registration NCT01716117). METHODS: Impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as 65 years and younger vs older than 65. Kaplan–Meier estimates of time to both endpoints, stratified by age, were created. Univariate predictors of time-to-stroke were analyzed using univariable proportional hazards regression models. Limited bivariable modeling was also attempted. RESULTS: Of 180 patients with large or giant IA enrolled, 119 were 65 years and younger, whereas 61 were older than 65 years. The 3-year risk of stroke for the older than 65 years group (19.7%) was more than double that of the 65 years and younger group (9.2%), P = .047. No new strokes were reported between 3 and 5 years. Four patients (2.2%) experienced aneurysm rupture within the first week post-treatment, 3 being 65 years and younger and the fourth older than 65 (>.99). Complete IA occlusion within age strata at 1 year was: older than 65 60% (33/55), 65 years and younger 79.1% (87/110), P = .009, 3 years: older than 65 67.6% (25/37), 65 years and younger 82.5% (66/80), P = .071, and 5 years: older than 65 85.7% (18/21), 65 years and younger 91.8% (56/61), P = .417. CONCLUSION: Age older than 65 was associated with an increased risk of stroke and predictive of incomplete healing and increased time to healing.
A Retrieval-Based Approach for Automatic Interpretation of Multi-Analyte Laboratory Profiles
Khandelwal, Sarthak, Leger, Rachel, Navitskas, Serena, Pruthi, Rajiv, Chen, Dong , Tavolara, Thomas E, Chen, Dong , Tavolara, Thomas Erol , Leger, Rachel, Navitskas, Serena D., Pruthi, Rajiv K. , Seheult, Jansen N.

Mayo Clinic

The Journal of Applied Laboratory Medicine | April 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jalm/jfag063 | PMID 42189159 Get It

Abstract Background Interpretation of multi-analyte laboratory profiles, such as lupus anticoagulant (LAC) testing, requires integration of numerous test results and clinical information. However, this process is time-consuming, requires domain knowledge, and has limited scalability. Given that rule-based systems are rigid and difficult to maintain and large language models pose risks of “hallucinations,” we developed and evaluated a novel retrieval-based approach to automate LAC profile interpretation to improve efficiency while maintaining fidelity and reliability for clinical use. Methods Our method processes laboratory values through ensemble random forest (RF) models to retrieve the most similar expert interpretation from a curated database of 347 previously interpreted LAC profiles. The system's performance was assessed through technical accuracy metrics, a work flow efficiency timing study, and expert review of interpretation accuracy for held-out cases. Results Technical validation demonstrated high accuracy in retrieving correct interpretative elements (median: 93% accuracy, interquartile range [IQR]: 67% to 100%). Retrieval accuracy was highly correlated with the prevalence of a given element (ρ = 0.8307). In a timing study of 93 consecutive LAC profiles, ensemble-assisted interpretation achieved a median time of 22 s per report (IQR: 16 s to 31 s), representing a 78.6% total reduction compared to manual interpretation (median: 118 s, IQR: 96 s to 172 s; t = 18.61, P &lt; 0.001). Furthermore, 92.5% of AI-assisted interpretations were completed within 60 s, exceeding the target of 85%. Expert review confirmed 100% concordance for LAC presence/absence. Conclusions The proposed approach significantly improves efficiency of complex laboratory interpretation for LAC profiles, while maintaining consistency and high fidelity. Future studies will explore the method’s inherent extensibility to the interpretation of other multi-analyte laboratory profiles.
Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including arterial divestment or arterial resection
Stoop, Thomas F, Land, Freek R. van ‘t , Seelen, Leonard W F, Ali, Mahsoem , Sultan, Ahmer , Javed, Ammar A, Eijck, van, Thiels, Cornelius A, Hewitt, D Brock, Sparrelid, Ernesto, Uzunoglu, Faik G, Gehrisch, O H Fiete, Daams, Freek, Ishida, Hiroyuki, Santvoort, Hjalmar C van, Molenaar, I Quintus, Leiting, Jennifer L. , Cappelle, Marie, Ginesini, Michael, Kendrick, Michael L, Franklin, Oskar , Ghorbani, Poya, Schulick, Richard D, Dankha, Rimon , Wilde, R F de, Welsch, Thilo , Riele, Wouter te, Wolfgang, Christopher L, Koerkamp, Bas Groot , Boggi, Ugo, Truty, Mark J, Chiaro, Marco Del, Hackert, T, Croce, C, Kazemier, G, Rompen, I F, Larsson, P, Franco, S Rodriguez, Sugawara, T, van 't Land, Freek R , Erdmann, Joris I , Busch, Olivier R , Franklin, Oskar , Besselink, Marc G , Groot Koerkamp, Bas , Hackert, Thilo , Sultan, Ahmer , Stoop, Thomas F. , Seelen, Leonard W. F. , Javed, Ammar A. , Thiels, Cornelius A. , Hewitt, D. Brock , Sparrelid, Ernesto , Uzunoglu, Faik Güntac , Gehrisch, O. H. Fiete, Daams, F, Ishida, Hiroyuki, Santvoort, Hjalmar C. van , Molenaar, I. Quintus , Erdmann, Joris I. , Cappelle, Marie , Ginesini, Michael , Kendrick, Michael L. , Napoli, Niccolò , Ghorbani, Poya , Schulick, Richard D. , Wilde, Roeland De, Riele, Wouter W. te , Wolfgang, Christopher L. , Boggi, Ugo , Truty, Mark J. , Chiaro, Marco Del , Hackert, Thilo , Kazemier, Geert , Rompen, Ingmar Florin , Larsson, Patrik , Franco, Salvador Rodriguez

Mayo Clinic

BJS Open | April 16, 2026 | Volume: 10 | Issue: 3 | Pages: No page available

10.1093/bjsopen/zrag058 | PMID 42263218 Get It

Abstract Background Some centres advocate preoperative radiotherapy in patients with pancreatic cancer and arterial involvement despite a lack of Level 1 evidence on survival benefit. Although it has been suggested that preoperative radiotherapy may increase the risk of postpancreatectomy haemorrhage (PPH) and morbidity, evidence is again lacking. This study investigated the association between preoperative radiotherapy and both PPH and major morbidity following arterial divestment/resection during pancreatic adenocarcinoma resection after chemotherapy. Methods Consecutive patients diagnosed with pancreatic adenocarcinoma and &gt; 180° arterial involvement who were treated with preoperative chemotherapy with or without radiotherapy followed by pancreatic resection with arterial divestment/resection were included in the study. Logistic regression analyses including propensity score-based overlap weighting were performed to investigate associations between radiotherapy and in-hospital PPH grade B/C and major morbidity, expressed as adjusted risk differences (aRDs). Results Overall, 246 patients undergoing pancreatic resection with arterial resection (169, 69%) or divestment (77, 31%) were included. Radiotherapy was not associated with PPH (aRD 6%; 95% confidence interval (c.i.) −3 to 14), regardless of arterial divestment (aRD 3%; 95% c.i. −5 to 11) or arterial resection (aRD 12%; 95% c.i. 1 to 23; Pinteraction = 0.189). Radiotherapy was associated with a 14% (95% c.i. 2 to 25) higher risk of major morbidity, especially after arterial resection (aRD 27%; 95% c.i. 11 to 43) compared with arterial divestment (aRD −12%; 95% c.i. −35 to 11; Pinteraction = 0.006) and after external beam radiotherapy (aRD 21%; 95% c.i. 8 to 32) compared with stereotactic body radiotherapy (aRD −12%; 95% c.i. −27 to 6; Pinteraction = 0.0001). Ninety-day mortality was increased, albeit not significantly, after preoperative radiotherapy (10 (8%) versus 3 (3%) deaths with versus without preoperative radiotherapy, respectively; P = 0.067). Conclusions Radiotherapy before resection of pancreatic cancer with &gt; 180° arterial involvement was associated with an increased risk of postoperative major morbidity when arterial resection, but not arterial divestment, was performed. This risk should be taken into account when considering preoperative radiotherapy in patients who may require arterial resection.